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Background/aim: Subthreshold yellow nondamaging retinal laser therapy (NRT) could provide a greater safety profile when
compared to conventional laser methods. NRT may also improve diabetic macular edema (DME). This study aims to assess whether
the severity of DME affects the efficacy of subthreshold yellow NRT.
Materials and methods: The study included 70 eyes that had previously been treated with ranibizumab for DME and then developed
recurrent macular edema, which was treated with NRT once. The central foveal thickness (CFT) and best-corrected visual acuity
(BCVA) were evaluated retrospectively 2 months following the NRT. The eyes in the study were divided into 4 different groups
according to the baseline CFT values. The initial CFT was 250–300 μm in Group 1 (n = 26), 301–400 μm in Group 2 (n = 24), and >401
μm in Group 3 (n = 20). Group 4 (n = 20) included control subjects with 250–300 µm CFT, diagnosed with DME, and not previously
treated. The alterations in the BCVA and CFT were measured.
Results: In the study, it was determined that 45 right eyes and 45 left eyes were involved. Statistically significant decrements (42.84
m reduction) in CFT were detected only in the Group 1 (p = 0.01). There was no significant improvement in CFT within Group 2, 3
and 4 (p = 0.29, p = 0.73, p = 0.22, respectively). Solely Group 1 had statistically significant improvement (from 0.54 to 0.39 LogMAR)
in BCVA (p = 0.01), while groups 2, 3 and 4 had no improvement at all (p = 0.74, p = 0.96, p = 0.66 respectively).
Conclusions: Based on the results, NRT provided an improvement in BCVA and CFT in eyes with CFT less than 300 µm at the shortterm follow-up. However, CFT and BCVA outcomes after NRT were inferior to those achieved after previous ranibizumab treatment.
No positive effect of NRT was not observed in patients with moderate and severe macular edema in DME treatment.
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1. Introduction
Numerous pathobiological alterations are leading to the
decreased visual acuity of patients with diabetic
retinopathy. The most important cause is diabetic macular
edema (DME) [1]. Many therapeutic options have been
used
to
manage
DME,
including
laser
photocoagulation/pharmacologic
therapy
like
intravitreal steroids and antivascular endothelial growth
factor (anti-VEGF) drugs [2]. However, the cost of steroid
and anti-VEGF treatments has been quite high. Currently,
the conventional laser is not a treatment option for DME.
The use of subthreshold retinal laser was first initiated
using a near-infrared (810 nm) diode laser in the late
1990s [3]. The nondamaging retinal laser therapy (NRT)
was recently defined. The nondamaging hyperthermia
was demonstrated in mice by observing the expression of
heat shock protein [4]. Based on those reported results,
the titration protocol has been developed by adjusting
laser power and duration. This protocol is called endpoint
management (EpM) and is related to the minimal tissue
effects in a visible titration [5]. The EpM laser therapy uses
an Arrhenius integral algorithm to control laser power
and pulse duration, optimizing the therapeutic effect of
the laser at subvisible levels [5].

The laser power is titrated to create a barely visible
lesion at a pulse duration of 15 or 20 ms, and EpM using
15 ms is called NRT [5,6]. The yellow laser (577 nm) is
suitable for macular disease. Because it is well absorbed
by melanin and hemoglobin and minimally absorbed by
macular xanthophylls. For this reason, it could be used for
the treatment over the fovea [7,8].
This study aims to assess the impact of DME severity
or central macular thickness on short-term NRT efficacy
and whether it can be used as a substitute for costly
intravitreal treatments.
2. Material and methods
This clinical study was conducted from January 2016 to
December 2017. Local ethical committee approval was
obtained by the local ethical committee of the Ankara
Numune Education and Research Hospital. The study was
conducted following the tenets of the Declarations of
Helsinki on medical research involving human subjects.
Informed consent was obtained from each participant.
DME was defined as hard exudate and/or retinal
thickening involving the central macula and fovea with
central foveal thickness (CFT) ≥ 250 µm on OCT. The cases
were selected from patients who had previously received
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3 or 4 consecutive monthly doses of ranibizumab for DME,
followed monthly, regressed macular edema and the
injection treatment was terminated. Among these
patients, those with recurrent macular edema during their
follow-up were included in the study. The patients were
treated with NRT laser for one session. The period
between the last ranibizumab treatment and NRT was
more than 2 months. The cases were examined 2 months
after the laser treatment. The CFT and best-corrected
visual acuity (BCVA) was assessed retrospectively 2
months after the NRT. Intravitreal ranibizumab injection
was administered again to patients whose BCVA
decreased and CFT increased in the 2nd month follow-up.
Patients
with
previous
conventional
laser
administration, intravitreal or subtenon steroid
injections, and patients with proliferative diabetic
retinopathy were excluded from the study. Patients with a
follow-up period of fewer than 6 months after laser and
patients with ischemic maculopathy were also excluded
from the study. Besides, patients with other retinal and
ocular diseases that affect BCVA were excluded from the
study.
All of the patients underwent routine ophthalmologic
examination. The spectral-domain optical coherence
tomography (Spectralis HRA+OCT, Heidelberg, Germany)
was performed before NRT and 2 months after NRT to
analyze CFT. Retinal thickness in the ETDRS subfields was
analyzed. For fundus autofluorescence images, 488 nm
wavelength was used and images were obtained. As
adverse effects of laser; scotoma declaration, the retinal
scar on clinical examination, retinal tissue damage on
fundus autofluorescence, and damage on optical
coherence tomography were recorded.
To evaluate the effect of NRT, eyes in the study were
divided into 4 different groups and the initial CFT values
were based on the grouping. The initial CFT was 250–300
μm in Group 1, 301–400 µm in Group 2, and >401 m in
Group 3. Group 4 included control patients, who had been
diagnosed with DME, had 250–300 µm CFT, had visual
acuity in the range of 20/40 to 20/20, had never been
treated and macular edemas were present in the OCT.
There was no atrophy and ellipsoid zone defect in the
initial and follow-up OCT. The change in CFT and BCVA
was evaluated before and after treatment.
The patients were treated with NRT once. The laser
was administrated with an Area-Centralis lens (Volk
Optical, USA). The NRT protocol was applied with yellow
light having a spectrum of 577 nm (Topcon Laser Systems,
USA) with the following parameters: 200 m spot size, 15
ms, 0.50 spacing, 30% EpM, off landmark. The power of
Table 1. Demographic data of patients in different groups.
Group 1
Group 2
n = 26 (eyes)
n = 24 (eyes)
Age
58.94
57.43
Mean range
(years)
(49–74)
(42–75)
Female
14
12
Gender
Male

12

12

the laser used in NRT for each eye was determined by test
burn. All eyes were treated by the same person according
to the OCT-based thickness map around the macula. Laser
applied to areas 500 microns away from the fovea center.
The test burn was performed outside the vascular arcade
with the power titrated from 100 mW upward until a burn
became barely visible. The maximum power was 150 mW.
Once the clinical threshold is determined, NRT was
applied by reducing this power level to 30%.
Data analysis was performed using IBM SPSS v. 22.0
for Windows (SPSS Inc., Chicago, IL, USA). Kolmogorov–
Smirnov test was applied to test the normality
assumption. Since the distribution of the test was
determined as normal, the parametric test was applied.
The paired t-test was used to compare changes in CFT and
BCVA in each group at baseline and after 2 months. Oneway ANOVA was used to evaluate differences in CFT and
BCVA among groups. Bonferroni test was used as post hoc
test after one-way ANOVA. The alterations in CFT and
BCVA between the control group and Groups 1, 2, and 3
were compared using independent sample t-tests. At the
beginning of this study, the intraclass correlation test was
performed because two eyes were included in the study.
The value was determined as 0.2. It was defined that there
was no problem with including two eyes in the study. The
p-value of less than 0.05 was considered statistically
significant.
3. Results
The study included 70 eyes with an average age of 59.15 ±
8.03 years (41–75 years). In the study, it was determined
that 45 right eyes and 45 left eyes were involved. There
were 26 eyes in Group 1, 24 eyes in Group 2, 20 eyes in
Group 3, and 20 eyes in Group 4. There was no statistically
significant difference in age and gender assessment
between the groups (p = 0.83 and p = 0.88). The
demographic characteristics of the patients are depicted
in Table 1.
The mean preoperative CFT was 319.93 ± 73.47 µ m.
In the 2nd month of follow-up, the CFT value in Group 1
decreased by 42.84 µm to 229.64 µ m, (p = 0.01) (Figures
1a-b). Scar and atrophic lesions caused by NRT lasers
were not recorded in the patient (Figures 1c–d). There
was no significant improvement in CFT values in Group 2,
3, and 4 (p = 0.29, p = 0.73, p = 0.22 respectively) (Figure
2A-B). Table 2 shows the mean CFT values for the baseline
and 2nd months of follow-up. Scar and atrophic lesions
caused by NRT lasers were also not recorded in patients
in these groups (Figure 2c-d).

Group 3
n = 20 (eyes)
60.82
(45–72)
10

Group 4
n = 20 (eyes)
59.86
(41–68)
12

10

8

P value
0.83
0.88
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Figure 1. Optical coherence tomography and fundus autofluorescence image of a patient who underwent nondamaging retinal laser
therapy. The central foveal thickness decreased from 271 µm (A) to 231 µ m (B) and the best-corrected visual acuity increased from
20/40 to 20/32. Fundus autofluorescence imaging demonstrated hyperautofluorescence spots in the fovea (C). After treatment,
hyperautofluorescence appearance decreased and autofluorescence alteration due to laser-related scar was not detected (D).

Figure 2. Optical coherence tomography and fundus autofluorescence image of another patient who underwent nondamaging
retinal laser therapy. The central foveal thickness increased from 421 µm (A) to 584 µ m (B) and best-corrected visual acuity
decreased from 20/200 to 20/400. Fundus autofluorescence imaging demonstrated hyperautofluorescence spots in the fovea (C).
After treatment, hyperautofluorescence appearance increased, however, autofluorescence alteration due to laser-related scar was
not detected (D).

The mean BCVA in Group 1 increased from 0.54
logarithm of the minimum angle of resolution (LogMAR)
to 0.39 LogMAR (p = 0.01). There was no significant
improvement in BCVA in Groups 2, 3, and 4 (p = 0.74, p =
0.96, p = 0.66 respectively). Table 2 also shows the mean
BCVA values for the baseline and 2nd months of followup.
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4. Discussion
The NRT is a treatment based on the adjustment of laser
power and pulse duration, concerning the titration
settings [9]. EpM algorithm is based upon the modeling of
the temperature-dependent rate of protein denaturation
[10,11]. In this algorithm, a barely seen lesion is obtained
first by laser power using pulses of 15 ms, and this
modality is called NRT. Since no tissue damage was
detected below 30% of energy on the EpM scale in animal
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Table 2. The mean central foveal thickness and best-corrected visual acuity of values at baseline and after nondamaging retinal
laser therapy.
Central foveal thickness
Visual acuity
(micron)
(The logarithm of the minimum angle of resolutionLogMAR)
Baseline
After laser
P-value Baseline
After laser
P-value
Group 1

272.48 ± 39.45 (257–296)

229.64 ± 38.68 (201–278)

0.01

0.54 ± 0.05

0.39 ± 0.06

0.01

Group 2

311.48 ± 49.75 (303–394)

317.68 ± 33.95 (295–451)

0.29

0.84 ± 0.14

0.87 ± 0.19

0.74

Group 3

435.02 ± 36.67 (423–546)

468.76 ± 48.72 (458–603)

0.73

1.30 ± 0.28

1.35 ± 0.37

0.96

Group 4

276.68 ± 41.42 (263–298)

298.44 ± 39.68 (281–328)

0.22

0.56 ± 0.05

0.62 ± 0.06

0.66

experiments [5], it is set to 30% for clinical applications of
NRT. Lavinsky et al. previously indicated that the heat
shock protein (HSP) expression in response to thermal
energy aids in defining the therapeutic window for NRT
[9]. They emphasized that tissue damage was not
determined, which allows high-density treatment on
fovea [10].
The stimulation of HSP helps to regenerate cellular
functions by refolding the damaged proteins. Moreover,
HSP-27 and HSP-70 have antiapoptotic functions in
degenerative processes [5]. Thus, just after the laser
therapy, increased synthesis of HSP and co-chaperones
may restore the normal physiology of retinal pigment
epithelium [9]. Lavinsky et al. [9] further investigated the
EpM protocol to evaluate the clinical effectiveness of NRT
in the treatment of chronic central serous
chorioretinopathy and macular telangiectasia. They
suggested that NRT is an effective and safe treatment
option for both diseases. They emphasized that in the
treatment of two separate disorders, upregulation of HSE
in the retinal pigment epithelium and glial fibrillary acidic
protein expression in Muller cells have been accomplished
by the activation of endogenous repair pathways. They
also proposed that NRT might be effective for the
treatment of many retinal diseases including macular
edema [9].
For diseases with primary pathology in the retinal
pigment epithelium, a yellow (577 nm) wavelength laser
is quite proper to use. It is mainly absorbed by melanin
and hemoglobin and is only minimally absorbed by
macular xanthophylls, which are important for the
protection of the fovea [7]. There are many studies
reporting improvement of DME after yellow laser
treatment [7–9]. In the present study, a yellow laser (577
nm) was used.
Many previous studies investigated the effectiveness
of subthreshold photocoagulation in DME [8]. Mansouri et
al. [12] investigated the importance of CFT with 810 nm
subthreshold micropulse treatment. They reported that
treatment responses were better in the patients with CFT
less than 400 µm than in patients with CFT greater than
400 m. In this study, patients with CFT less than 400 µm
were divided into 2 groups (250–300 µm and 300–400
µm) for further evaluation. According to the results, after
2 months of NRT, statistically significant CFT reduction
and significant BCVA raise are observed in patients with
pre-treatment CFT of 300 µm or lower. The cause of

failure associated with CFT increase can be explained by a
few theories. First, the distribution of laser energy might
change in patients with high CFT values. Secondly, it is
thought that NRT stimulates retinal pigment epithelium
cells by the release of cytokines. These cytokines restore
the pump function of retinal pigment epithelium and
cause the absorption of sub-retinal and intra-retinal fluid
[13]. A high amount of edema can dilute the concentration
of these cytokines. It can be achieved by arranging laser
parameters according to CFT values or macular edema
might be reduced with pharmacological therapy before
the application of NRT.
According to previous studies, half of the reduction in
macular edema after subthreshold micro-pulse laser
occurs 2–3 months after treatment. In the study of Luttrull
et al. [14], most of the patients responded within 2–3
months after the subthreshold laser application. In this
study, the duration of the above studies was taken into
consideration and 2nd month was chosen as the evaluation
time of the effectiveness of the laser to avoid further
deterioration of the clinical conditions of the patients.
Intravitreal injection was administered to the patients
with decreasing BCVA and increasing CFT values in the
2nd month [5,14]. Using anti-VEGF as rescue therapy is an
important step in DME cases with a poor or negative
response to steroids or lasers [15]. In this study,
ranibizumab was used again to avoid further loss in
patients with post-laser edema.
There are theoretical additional advantages of EpM
compared to subthreshold micropulse photocoagulation.
Firstly, EpM has titration protocols that control the power
and exposure time of the laser. Secondly, the duration of
the pulse with EpM is shorter than the duration of the
micropulse. Thirdly, the EpM has the landmark pattern
feature, which enables us to treat lesions subvisible, while
leaving visible markers for reference and documentation
of the treatment region. And EpM can be repeated as often
as necessary [16].
The limitations of this study are the small sample size
and evaluation after 2 months of follow-up. Also, the
history/measurement of confounding factors like
duration of diabetes, type of diabetes, hypertension,
smoking history, control or un-control of diabetes, lipid
profile, and s-creatinine weren’t measured. Additionally,
both eyes of the subjects were included in the study, and
in some cases, there was a difference between the severity
of DME levels of the right and left eye of the same patient.
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So, the systemic disease may bring a bias for the study. To
our knowledge, there is no study comparing the
effectiveness of NRT compared to the anatomical severity
of DME. From this point of view, the strong side of the
study is revealed.
It is reported that by using the landmark pattern
feature, the surgeon can choose to leave visible markers
for reference and documentation of the treatment region
[16]. In that study, the presence of markers or atrophic
lesions after NRT therapy was not observed with fundus
autofluorescence during the follow-up (Figures 1c-d and
2c-d). In addition to the mechanism of the NRT laser, it can
be speculated that bringing the landmark to the off
position may have contributed to this situation.
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